biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
biote Corp.NASDAQ: BTMD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 research & development of $0 is the 10th highest of the 11 companies compared; the peer median is $27.1M.
- Research & development amounts to 0.0% of revenue for BTMD, versus a peer median of 57.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $312.43M | +226.5% | +70.8% | — | |
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $37.82M | -33.6% | -23.5% | 3297.1% | |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
| LTM Mar 2026 | $26.42M | +16.3% | +12.0% | 22.7% | |
| LTM Mar 2026 | $21.46M | +138.8% | +31.8% | 63.4% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M | -35.9% | -14.4% | — |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BTMD) | $27.1M | -9.9% | +12.0% | 57.0% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.4M | 164.96M | 185.36M | 197.19M | 192.22M |
| Cost of Revenue | 48.82M | 54.58M | 57.88M | 58.13M | 58.13M |
| Gross Profit | 90.58M | 110.38M | 127.48M | 139.06M | 134.09M |
| Gross Margin | 65.0% | 66.9% | 68.8% | 70.5% | 69.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 53.96M | 171.1M | 98.83M | 107.45M | 94.97M |
| Operating Expenses | 56.02M | 171.1M | 98.83M | 107.45M | 94.97M |
| Depreciation & Amortization | 1.4M | 2.2M | 794K | 3.57M | 3.67M |
| EBITDA | 35.98M | 7.96M | 39.54M | 15.59M | 53.12M |
| EBITDA Margin | 25.8% | 4.8% | 21.3% | 7.9% | 27.6% |
| Operating Income | 34.56M | (60.72M) | 28.66M | 31.61M | 39.12M |
| Operating Margin | 24.8% | -36.8% | 15.5% | 16.0% | 20.4% |
| Interest Income | 0 | 0 | 0 | 0 | 900K |
| Interest Expense | 1.67M | 4.05M | 6.36M | 11M | 11.86M |
| Other Income / Expenses | (1.66M) | 62.43M | (28.78M) | (30.6M) | (1.54M) |
| Income Before Tax | 32.91M | 1.71M | (123K) | 1.02M | 37.58M |
| Pre-Tax Margin | 23.6% | 1.0% | -0.1% | 0.5% | 19.6% |
| Income Tax Expense | 286K | 388K | 2.68M | 970K | 5.99M |
| Net Income | 32.62M | (969K) | 3.32M | 3.16M | 27.05M |
| Net Margin | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% |
| EPS (Basic) | (0.87) | 0.16 | 0.13 | 0.09 | 0.86 |
| EPS (Diluted) | (0.87) | 0.16 | 0.13 | 0.09 | 0.74 |
| Weighted Avg Shares | 7.57M | 8.06M | 25.71M | 34.27M | 31.28M |
| Weighted Avg Shares (Diluted) | 7.57M | 8.06M | 25.71M | 34.27M | 36.67M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.